GlassScriptPhysician profile
Francis C Noonan, JR.
NPI 1952379059
$918.61
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $167 · 2021: $310 · 2022: $172.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $254.78 | 2019-2021 | |
| Abbvie INC. | $219.74 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $75.11 | 2022 | |
| Ibsa Pharma INC. | $52.61 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.42 | 2022 | |
| Novo Nordisk INC | $34.03 | 2020-2021 | |
| Pfizer INC. | $32.57 | 2021 | |
| Amarin Pharma, INC. | $29.90 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $29.84 | 2021 | |
| Merck Sharp & Dohme LLC | $28.34 | 2021 | |
| Romark Laboratories, Lc | $28.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.27 | 2020 | |
| Lilly USA, LLC | $22.45 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Noonan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.